9MNZ image
Deposition Date 2024-12-24
Release Date 2025-03-05
Last Version Date 2025-06-04
Entry Detail
PDB ID:
9MNZ
Title:
Cryo-EM structure of human MPC in complex with UK5099 in nanodiscs
Biological Source:
Source Organism:
Mus musculus (Taxon ID: 10090)
synthetic construct (Taxon ID: 32630)
Homo sapiens (Taxon ID: 9606)
Escherichia coli (Taxon ID: 562)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.73 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Mitochondrial pyruvate carrier 1
Gene (Uniprot):MPC1
Chain IDs:D (auth: A)
Chain Length:115
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Mitochondrial pyruvate carrier 2
Gene (Uniprot):MPC2
Chain IDs:C (auth: B)
Chain Length:127
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Nanobody
Chain IDs:B (auth: C)
Chain Length:152
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polypeptide(L)
Molecule:Fab_8D3_2 heavy chain
Chain IDs:A (auth: D)
Chain Length:265
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Fab_8D3_2 light chain
Chain IDs:F (auth: E)
Chain Length:247
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:MBP-PrA/G
Chain IDs:E (auth: F)
Chain Length:545
Number of Molecules:1
Biological Source:Escherichia coli
Ligand Molecules
Primary Citation
Structure of mitochondrial pyruvate carrier and its inhibition mechanism.
Nature 641 250 257 (2025)
PMID: 40044865 DOI: 10.1038/s41586-025-08667-y

Abstact

The mitochondrial pyruvate carrier (MPC) governs the entry of pyruvate-a central metabolite that bridges cytosolic glycolysis with mitochondrial oxidative phosphorylation-into the mitochondrial matrix1-5. It thus serves as a pivotal metabolic gatekeeper and has fundamental roles in cellular metabolism. Moreover, MPC is a key target for drugs aimed at managing diabetes, non-alcoholic steatohepatitis and neurodegenerative diseases4-6. However, despite MPC's critical roles in both physiology and medicine, the molecular mechanisms underlying its transport function and how it is inhibited by drugs have remained largely unclear. Here our structural findings on human MPC define the architecture of this vital transporter, delineate its substrate-binding site and translocation pathway, and reveal its major conformational states. Furthermore, we explain the binding and inhibition mechanisms of MPC inhibitors. Our findings provide the molecular basis for understanding MPC's function and pave the way for the development of more-effective therapeutic reagents that target MPC.

Legend

Protein

Chemical

Disease

Primary Citation of related structures